Loading...

BCDA BIOCARDIA INC US FDA Inspections 8-K Filing

BCRD

BCD

BIOCARDIA INC

(BCDA)

2025 8-K

Show Summary

Summary

Clinical Trials

Geographic Expansion

Equity Offerings

Other Special Situation

Financial Statements

New Product Launches

Clinical Trials

Equity Offerings

Trial Enrollment

Nasdaq Compliance

Conference Call

Clinical Trial Results

Financial Results

Trial Enrollment Complete

Conference Presentation

Regulatory Update

Financial Results

Clinical Trial Update

Nasdaq Compliance

Public Offering

Public Offering

Financial Results

Patent Issuance

Collaborative Phase II Tria...

Patent Issuance

Reverse Stock Split

Annual Meeting and Reverse ...

Financial Results Announcement

Financial Results Announcement

Partnership Announcement

Other Special Situation

Announcement of Positive In...

Private Placement

Announcement of Scientific ...

At The Market Offering Agre...

Update on Stockholder Advis...

Extension of Proposal Deadline

Update on CardiAMP autologo...

Securities Purchase Agreement

FDA Approval for Phase III ...

Financial Results Announcement

Annual Meeting of Stockholders

Earnings Reports

Product Updates

Market Expansion

Termination of Agreement an...

Securities Purchase Agreement

Suspension of Sales

FDA Review Completion for C...

Financial Results Announcement

Patent Issuance

Amended Bylaws Approval

Announcement of Presentations

Patent Issuance

External Links:

On April 15, 2025, BioCardia, Inc. announced that the Data Safety Monitoring Board recommended continuing their CardiALLO Allogeneic Cell Therapy trial, noting no major adverse events or immune reactions. This indicates positive safety data from the trial's 30-day review.

AI Assistant

BIOCARDIA INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.